US EditionLUPIN AND HONEYWELL MOVE FORWARD JOINTLY WITH PLANS FOR HFO TECHNOLOGY IN INHALERS
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
LUPIN AND HONEYWELL MOVE FORWARD JOINTLY WITH PLANS FOR HFO TECHNOLOGY IN INHALERS
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants Global pharma major Lupin Limited (Lupin) announced today its plan to use Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with …
Lupin collaborates with Honeywell, plans for HFO technology in Inhalers - Express Pharma
Lupin announced its plan to use Honeywell’s Solstice Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules. Lupin intends to become the first pharmaceutical company in India to use Honeyw…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
